Indications
Treatment of difficult cases of respiratory, dermatologic and ocular allergies, as well as ocular inflammatory disorders, where adjunctive systemic corticosteroid therapy is indicated.
Contraindications
Patients with known hypersensitivity to any component of the formula. Children under 6 years. Patients receiving monoamine oxidase (MAO) inhibitors therapy. Patients with systemic fungal infections. Gastro-duodenal ulcer. Narrow-angle glaucoma. Prostatic hypertrophy or bladder neck obstruction.
Compositon/Ingredients
Betamethason 0.25mg, Dexchlorpheniramin 2mg
Dosage and administration
Adults and children > 12 years: initial with 1-2 tablets 4 times daily, after meals and at bedtime. Do not exceed 8 tablets daily. Children 6-12 years: ½ tablet 3 times daily. An additional daily dose is required if necessary. Do not exceed 4 tablets daily.
Precaution
Stadexmin contains lactose. Patients with rare hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption should not take this medicine. Stadexmin contains the azo colouring agents e.g., sunset yellow and ponceau 4R, which may cause allergic reactions. Extreme caution should be exercised when use Stadexmin for: The elderly (> 60 years) and children. Pregnancy and breastfeeding women. Patients with congestive heart failure, recent myocardial infarction, or hypertension, in patients with diabetes mellitus, epilepsy, glaucoma, hypothyroidism, hepatic failure, osteoporosis, peptic ulceration, psychoses or severe affective disorders, and renal impairment. Patients with non-immune with chickenpox, herpes zoster and measles. Patients with angle-closure glaucoma, urinary retention, prostatic hyperplasia, or pyloroduodenal obstruction due to its anticholinergic adverse effects. Stadexmin is not recommended in the presence of acute infections uncontrolled by appropriate antimicrobial therapy, patients with active or doubtfully quiescent tuberculosis. Live vaccines should not be given to patients receiving Stadexmin nor for at least 3 months afterwards; killed vaccines or toxoids may be given although the response may be attenuated. During prolonged Stadexmin using, patients should be examined regularly. Sodium intake may need to be reduced and calcium and potassium supplements may be necessary. Stadexmin can cause drowsiness, dizziness and psychomotor impairment in some patients. This is accentuated by taking alcoholic beverages or medicines containing alcohol or other sedatives. Stadexmin Should be avoided when driving and controlling machine.
Storage
Store at temperature below 30°C, protect from light.
